Trump Sues BBC for Defamation Over Edited Capitol Riot Speech Clip 
SpaceX Begins IPO Preparations as Wall Street Banks Line Up for Advisory Roles 
SUPERFORTUNE Launches AI-Powered Mobile App, Expanding Beyond Web3 Into $392 Billion Metaphysics Market 
Coca-Cola’s Proposed Sale of Costa Coffee Faces Uncertainty Amid Price Dispute 
Nvidia Weighs Expanding H200 AI Chip Production as China Demand Surges 
Biren Technology Targets Hong Kong IPO to Raise $300 Million Amid China’s AI Chip Push 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
United Airlines Tokyo-Bound Flight Returns to Dulles After Engine Failure 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
Ford Takes $19.5 Billion Charge as EV Strategy Shifts Toward Hybrids 
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
noyb Files GDPR Complaints Against TikTok, Grindr, and AppsFlyer Over Alleged Illegal Data Tracking. 
Korea Zinc Plans $6.78 Billion U.S. Smelter Investment With Government Partnership 
FAA Unveils Flight Plan 2026 to Strengthen Aviation Safety and Workforce Development 
Woolworths Faces Fresh Class Action Over Alleged Underpayments, Shares Slide 
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
EMERYVILLE, Calif., Nov. 08, 2016 -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, today announced that Stephen J. Farr, Ph.D., President and CEO, will participate in a fireside chat at the Stifel 2016 Healthcare Conference.
Stifel 2016 Healthcare Conference
| Date: | Tuesday, November 15, 2016 | |
| Time: | 3:45 pm Eastern Time / 12:45 pm Pacific Time | |
| Location: | New York, NY |
The presentation will be webcast live and can be accessed on Zogenix's Investor Relations website at ir.zogenix.com.
About Zogenix
Zogenix, Inc. (Nasdaq:ZGNX) is a pharmaceutical company committed to developing and commercializing CNS therapies that address specific clinical needs for people living with orphan and other CNS disorders who need innovative treatment alternatives to improve their daily functioning.
For more information, visit www.zogenix.com.
CONTACT: Investors: Andrew McDonald Founding Partner, LifeSci Advisors LLC 646-597-6987 | [email protected]
